Floatz logo

Prostvac®-Vf/Tricom™

Prostatic Neoplasms

Medical University of South CarolinavaccinePhase 2Dormant
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
60/ 100
Competitive Position
73/ 100

Competitive context

74 Active assets in the Prostatic Neoplasms cohort.

Asset / SponsorPhaseRating
Docetaxel
Merck Sharp & Dohme LLC
Phase 4BBB
Degarelix
Novartis Pharmaceuticals
Phase 4BBB
PREDNISONE TABLETS
Merck Sharp & Dohme LLC
Phase 3BBB
LEUPROLIDE
Dana-Farber Cancer Institute
Phase 4BB
Abiraterone Acetate
Qilu Pharmaceutical Co., Ltd.
Phase 3BB

View all 50 →

Same molecule, other indications

Prostvac®-Vf/Tricom™ is also rated in:

prostate cancerDormant
B
Indicative ·
62 / 100
View asset →
metastatic prostate carcinomaDormant
B
Indicative ·
60 / 100
View asset →
prostate carcinomaDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →